Oncology

News

Takeda and Protagonist's hepcidin mimetic rusfertide is the first hepcidin mimetic to be approved by the FDA for blood cancer polycythaemia vera.

News

New analysis from Tufts CSDD and Medable shows AI agent value to oncological drug development programmes at up to $21m each.

News

In another blow to its late-stage pipeline, AstraZeneca has pulled the plug on a phase 3 trial of its lung cancer treatment volrustomig.

News

Bristol Myers Squibb's CELMoD pipeline has delivered its first approval, for iberdomide, as part of a combination regimen for multiple myeloma.

News

ADC Therapeutics' chances of upgrading its accelerated approval for DLBCL therapy Zynlonta to a full approval have taken a knock.

News

ITM's first attempt to score FDA approval for one of its radiopharma therapies has been knocked back by the agency.